Accueil>>Signaling Pathways>> Others>> FLAP>>MK 886

MK 886 (Synonyms: L-663,536)

Catalog No.GC12277

MK 886 (L 663536) est un inhibiteur puissant, perméable aux cellules et oralement actif de la biosynthèse des FLAP (IC50 de 30 nM) et des leucotriènes (IC50 de 3 nM et 1,1 μM dans les leucocytes intacts et le sang total humain). MK 886 est également un antagoniste non compétitif de PPARα et peut induire l'apoptose.

Products are for research use only. Not for human use. We do not sell to patients.

MK 886 Chemical Structure

Cas No.: 118414-82-7

Taille Prix Stock Qté
10mg
111,00 $US
Ship Within 7 Days
50mg
380,00 $US
Ship Within 7 Days

Tel:(909) 407-4943 Email: sales@glpbio.com

Avis des clients

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

MK-886 (L 663536) is a 5-lipoxygenase-activating protein inhibitor and a leukotriene biosynthesis inhibitor (IC50=2.5 nM).

References:
[1]. [1] Kehrer JP et al. Inhibition of peroxisome-proliferator-activated receptor (PPAR)alpha by MK886. Biochem J. 2001 Jun 15.
[2]. [2] Gillard J et al. L-663,536 (MK-886) (3-[1-(4-chlorobenzyl)-3-t-butyl-thio-5-isopropylindol-2-yl]-2,2 - dimethylpropanoic acid), a novel, orally active leukotriene biosynthesis inhibitor. Can J Physiol Pharmacol. 1989 May;67(5):456-64.
[3]. [3] Dixon RA et al. Requirement of a 5-lipoxygenase-activating protein for leukotriene synthesis. Nature, 1990 Jan 18, 343(6255):282-4.http://www.ncbi.nlm.nih.gov/pubmed/2300173

Avis

Review for MK 886

Average Rating: 5 ★★★★★ (Based on Reviews and 22 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for MK 886

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.